Oral Webinar | Update on Medication-Related Osteonecrosis of the Jaw: Epidemiological and Diagnostic Aspects
the chair
MRONJ is still a condition with uncertain and controversial issues.
It is necessary for the international community to develop common diagnostic methods and strategies for the prevention and treatment of medication-related osteonecrosis of the jaw (MRONJ).
The aim of these two webinars is to provide an ample perspective on several debated aspects of MRONJ including risk estimates, disease definition and diagnostic pathway, individual risk assessment, and the fundamental role of imaging in the diagnosis, classification, and management of MRONJ.
Date: 24 November 2023 at 9.00 a.m. CET | 3:00 a.m. EST | 4:00 p.m. CST Asia
Webinar ID: 883 3138 2571
Webinar Secretariat: journal.webinar@mdpi.com
Meet the Event Chair
Meet Our Speakers
Dr. Vittorio Fusco
Oncology Unit, Azienda Ospedaliera di Alessandria SS, Antonio e Biagio e Cesare Arrigo, Alessandria, Italy;
Dr. Fusco is a physician at the Oncology Unit of Azienda Ospedaliera “SS. Antonio e Biagio e C. Arrigo”.
Dr. Fusco is the author and co-author of many scientific publications, including chapters of books and articles in local and international publications.
Dr. Fusco is a frequent speaker at congresses, meetings, conferences, and conventions and has organized local congresses and conventions.
Memberships
• Active Member of the Italian Association of Medical Oncology (AIOM)
• Active Member of the European Society of Medical Oncology (ESMO)
• Active Member of the Italian Network of Supportive Care in Cancer (NICSO)
• Active Member of the Multinational Association of Supportive Care in Cancer (MASCC)
• Active Member of the Italian Society of Osteoncology (ISO)
• Active Member of the Italian Society of Oral Pathology and Medicine (SIPMO)
Dr. Rodolfo Mauceri
University of Palermo, Palermo, Italy, Department of Rehabilitation, Fragility and Continuity of Care, Unit of Oral Medicine, University Hospital Palermo, Palermo, Italy;
Currently, he is a researcher at the Department of Oncological, Surgical and Stomatological Disciplines (DiChirOnS) of the University of Palermo (UNIPA, Italy: https://www.unipa.it/persone/docenti/m/rodolfo.mauceri/?pagina=curriculum).
At the moment, his research concerns the study of oral microbiota in patients with oral carcinoma and the prevention and treatment of medication-related osteonecrosis of the jaw.
He completed an international joint Ph.D. Program in “Oncology and Experimental surgery” (Cycle XXIX—UNIPA and Universiteit Antwerpen, Belgium); during the Ph.D. program, he also undertook a fellowship program in Head–Neck and Oral Oncology at the Universiteit Antwerpen. In February 2022, he completed his studies at the Postgraduate School of Oral Surgery of the Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina (Italy).
He is the author/co-author of several scientific articles in international and national journals (Scopus): https://www.scopus.com/authid/detail.uri?authorId=57195263668).
He is an active member of the Italian Society of Oral Pathology and Medicine (SIPMO); the Italian Society of Odontostomatological Surgery (SIdCO); and the Academy of Non-Transfusional Hemo-Components (ANTHEC).
Prof. Dr. Ourania Nicolatou-Galitis
CureCancer PC, Athens, Greece;
Dr Ourania Nicolatou-Galitis graduated from the Dental School of the National and Kapodistrian University of Athens—NKUA. She obtained her master’s degree and Certificate in Oral Pathology from Temple University, Philadelphia, USA. She served at the Dental School, NKUA, at all grades of responsibility, until 2020.
Current positions:
• Director and owner of a private dental and dental/oral oncology clinical practice, Athens, Greece, dentaloncology.gr
• Founding member and scientist responsible for CureCancer.gr and CureCancer.eu, organizer of seminars on dental oncology for dentists: https://curecancer.eu/news/post/webinar-dental-management-of-the-cancer-patient
• Founding member and Vice President of the Board of the Hellenic Society of Head and Neck Cancer, headneckcancer.gr
• Member of the EU Task Force for MRONJ
Past positions
• She has served as the scientist responsible for oral mucositis in cancer patients in the educational program of the British Medical Journal Best Practice: https://bestpractice.bmj.com/.
• She organized the educational program for MRONJ of ecancer—ecancerMedicalSciences: ecancer.org.
• Past President of the International Society of Oral Oncology-ISOO, 2017–2019
• MASCC Strategic Planning Committee, mascc.org, 2017–2020
• Chair of the Bone Study Group, mascc.org, 2015–2020
• Principal investigator for the AMGEN Registry Study for osteonecrosis in the Athens Dental School Center.
Major clinical interest, authorship, and honors
• Osteonecrosis of the jaw in medication is currently the main clinical and research focus of Dr. Ourania Nicolatou-Galitis. She serves as a referral center for many cancer centers in Greece.
• Author of several publications on medication-related osteonecrosis of the jaw (MRONJ). She was the first to document necrosis of the jawbone prior to the bone-exposed stage.
• She has been honored with international awards
Prof. Dr. Noam Yarom
Oral Medicine Unit, Sheba Medical Center, Tel Hashomer, Israel;
Prof. Noam Yarom is the Head of Oral Medicine at the Sheba Medical Center, Tel Hashomer, Israel, and a clinical associate professor at the School of Dental Medicine, Tel-Aviv University, Tel-Aviv, Israel. Prof. Yarom is the President of the International Society of Oral Medicine (ISOO) and a past president of the Israeli Society of Oral Medicine (ISOM). He is involved in developing clinical practice guidelines and position papers for major international organizations such as the American Society of Clinical Oncology (ASCO) and the Multinational Association of Supportive Care in Cancer / International Society of Oral Oncology (MASCC/ISOO). Prof. Yarom has served as a co-chair of the MASCC/ISOO/ASCO clinical practice guidelines on the prevention and management of medication-related osteonecrosis of the jaw (MRONJ).
His main research interests are the oral toxicities of cancer therapy and the quality of life of cancer patients, and he has published extensively on these topics.
Prof. Dr. Umberto Romeo
Department of Oral Sciences and Maxillofacial Surgery, Universita degli Studi di Roma La Sapienza, Rome, Italy;
A Full professor of Oral Medicine and Pathology of Sapienza University of Rome. Elect Director of the Department of Oral Sciences and Maxillofacial Surgery. Specialist in oral surgery. Director of the European master’s degree on Oral Laser Applications (EMDOLA) of Sapienza University of Rome. Academic Coordinator for the International Mobility Erasmus+ Faculty of Medicine and Dentistry. Vice President of SIPMO (Italian Society of Oral Pathology and Oral Medicine). Member of the Board of the World Federation for Laser Dentistry (WFLD). Past President of the Italian Society of Laser in Dentistry (SILO). He has published several scientific articles in national and international journals.
Prof. Dr. Alberto Bedogni
Regional Center for Prevention, Diagnosis and Treatment of Medication and Radiation-Related Bone Diseases of the Head and Neck, University of Padua, Padua, Italy, Department of Neuroscience, University of Padova, Padua, Italy;
Dr. Alberto Bedogni has been the Director of the Regional Center for the Prevention, Diagnosis and Treatment of Medication and Radiation-related Bone Diseases of the Head and Neck since 2014. He is an Assistant Professor of Maxillofacial Surgery at the Department of Neurosciences—DNS, University of Padua, and a consultant at the Unit of Maxillofacial Surgery, Hospital Trust of Padua. He is a fellow of the European Board of Maxillofacial Surgery (FEBOMS).
His basic and clinical research focuses on osteonecrosis of the jaw, bio-molecular markers in head and neck cancer, peripheral nerve regeneration, regenerative medicine, and the development of CAD-CAM customized titanium devices for jawbone reconstruction.
He is the founding member of the Expert Panel Committee of the Italian Societies of Oral Medicine and Pathology (SIPMO) and Maxillofacial Surgery (SICMF) and is the co-author of the Italian Recommendations for the Prevention, Diagnosis and Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ), first published in 2013 and edited in 2020. He has also actively contributed to the preparation of the guidelines on the prevention of bisphosphonate-related ONJ in the cancer population on behalf of the Italian Ministry of Health (2014).
He is the coordinator of a research team who have published several highly cited clinical papers in the last 20 years on the pathogenesis, prevention, diagnosis, and treatment of MRONJ. He has contributed to developing an international network of clinical research centers and has promoted several multicenter studies on MRONJ. Finally, he is a founding member of the European Task Force on Medication-Related Osteonecrosis of the Jaw.
Sponsors and Partners
Organizer
Patronage
Currently, MRONJ is still a condition with uncertain and controversial issues.
In the present Webinar, the participants had the chance to amplify their knowledge on several debated aspects of MRONJ.
The invited speakers were six researchers from different countries who have studied several aspects of MRONJ, publishing numerous articles on the subject in international journals.
They gave their perspective on epidemiology, risk estimates, disease definition and diagnostic pathway, individual risk assessment, and the fundamental role of imaging in the diagnosis, classification, and management of MRONJ.
The webinar was hosted via Zoom and required registration to attend. The full recording can be found below. In order to learn about future webinars, you can sign up to our newsletter by clicking “Subscribe” at the top of the page
"Medication-Related Osteonecrosis of the Jaw (MRONJ): Current Practice, New Tools and Future Trends"
Topical Collection Editors: Prof. Dr. Giacomo Oteri, Prof. Dr. Umberto Romeo, Dr. Rodolfo Mauceri, Prof. Dr. Alberto
Bedogni and Dr. Vittorio Fusco